WO2007112703A3 - Composición farmacéutica que comprende la proteína nmb0606 - Google Patents

Composición farmacéutica que comprende la proteína nmb0606 Download PDF

Info

Publication number
WO2007112703A3
WO2007112703A3 PCT/CU2007/000013 CU2007000013W WO2007112703A3 WO 2007112703 A3 WO2007112703 A3 WO 2007112703A3 CU 2007000013 W CU2007000013 W CU 2007000013W WO 2007112703 A3 WO2007112703 A3 WO 2007112703A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
nmb0606 protein
pharmaceutical composition
nmb0606
protein
Prior art date
Application number
PCT/CU2007/000013
Other languages
English (en)
French (fr)
Other versions
WO2007112703A2 (es
Inventor
Feyt Rolando Pajon
Acosta Karem Cobas
Negrin Yasser Perera
Garcia Gretel Sardinas
Diaz Darien Garcia
Blanco Sonia Gonzalez
Original Assignee
Ct Ingenieria Genetica Biotech
Feyt Rolando Pajon
Acosta Karem Cobas
Negrin Yasser Perera
Garcia Gretel Sardinas
Diaz Darien Garcia
Blanco Sonia Gonzalez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech, Feyt Rolando Pajon, Acosta Karem Cobas, Negrin Yasser Perera, Garcia Gretel Sardinas, Diaz Darien Garcia, Blanco Sonia Gonzalez filed Critical Ct Ingenieria Genetica Biotech
Priority to US12/295,198 priority Critical patent/US20100129387A1/en
Priority to BRPI0709922-3A priority patent/BRPI0709922A2/pt
Priority to AU2007234214A priority patent/AU2007234214A1/en
Priority to CA002647465A priority patent/CA2647465A1/en
Priority to MX2008012665A priority patent/MX2008012665A/es
Priority to EP07721809A priority patent/EP2011509A2/en
Publication of WO2007112703A2 publication Critical patent/WO2007112703A2/es
Publication of WO2007112703A3 publication Critical patent/WO2007112703A3/es
Priority to NO20084525A priority patent/NO20084525L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con el campo de la medicina, particularmente con el desarrollo de una composición farmacéutica que comprende la proteína NMB0606. La composición de la presente invención confiere protección contra diferentes enfermedades, causadas o no por patógenos. La proteína NMB0606 se identificó como componente de las preparaciones de vesículas de membrana externa (VME) de Neisseria meningitidis, se obtuvo mediante la tecnología del ácido desoxirribonucleico (ADN) recombinante y se evaluó su inmunogenicidad y actividad protectora en modelos animales. Por el elevado grado de conservación del gen que codifica para la proteína NMB0606, la composición que la comprende posee alto valor como antígeno inductor de una respuesta inmune de amplia reactividad. La composición de esta invención es aplicable en la medicina humana.
PCT/CU2007/000013 2006-03-31 2007-03-29 Composición farmacéutica que comprende la proteína nmb0606 WO2007112703A2 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US12/295,198 US20100129387A1 (en) 2006-03-31 2007-03-29 Pharmaceutical composition containing the nmb0606 protein
BRPI0709922-3A BRPI0709922A2 (pt) 2006-03-31 2007-03-29 composiÇço farmacÊutica contendo a proteÍna nmb0606
AU2007234214A AU2007234214A1 (en) 2006-03-31 2007-03-29 Pharmaceutical composition containing the NMB0606 protein
CA002647465A CA2647465A1 (en) 2006-03-31 2007-03-29 Pharmaceutical composition containing the nmb0606 protein
MX2008012665A MX2008012665A (es) 2006-03-31 2007-03-29 Composicion farmaceutica que comprende la proteina nmb0606.
EP07721809A EP2011509A2 (en) 2006-03-31 2007-03-29 Pharmaceutical composition containing the nmb0606 protein
NO20084525A NO20084525L (no) 2006-03-31 2008-10-28 Farmasoytiske sammensetninger inneholdende NMB0606-protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20060075A CU23575A1 (es) 2006-03-31 2006-03-31 Composición farmacéutica que comprende la proteína nmb0606
CU2006-0075 2006-03-31

Publications (2)

Publication Number Publication Date
WO2007112703A2 WO2007112703A2 (es) 2007-10-11
WO2007112703A3 true WO2007112703A3 (es) 2008-04-24

Family

ID=38535626

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2007/000013 WO2007112703A2 (es) 2006-03-31 2007-03-29 Composición farmacéutica que comprende la proteína nmb0606

Country Status (13)

Country Link
US (1) US20100129387A1 (es)
EP (1) EP2011509A2 (es)
KR (1) KR20080108576A (es)
CN (1) CN101448518A (es)
AR (1) AR060797A1 (es)
AU (1) AU2007234214A1 (es)
BR (1) BRPI0709922A2 (es)
CA (1) CA2647465A1 (es)
CU (1) CU23575A1 (es)
MX (1) MX2008012665A (es)
NO (1) NO20084525L (es)
WO (1) WO2007112703A2 (es)
ZA (1) ZA200808768B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3506935T1 (sl) 2016-09-02 2024-06-28 Sanofi Pasteur, Inc. Cepivo proti neisseriji meningitidis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071725A2 (en) * 1999-05-19 2000-11-30 Chiron S.P.A. Combination neisserial compositions
WO2002079243A2 (en) * 2001-02-12 2002-10-10 Chiron Srl. Gonococcal proteins and nucleic acids
WO2005054282A1 (es) * 2003-12-03 2005-06-16 Centro De Ingenieria Genetica Y Biotecnologia Proteína nmb0928 y su uso en formulaciones farmaceuticas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071725A2 (en) * 1999-05-19 2000-11-30 Chiron S.P.A. Combination neisserial compositions
WO2002079243A2 (en) * 2001-02-12 2002-10-10 Chiron Srl. Gonococcal proteins and nucleic acids
WO2005054282A1 (es) * 2003-12-03 2005-06-16 Centro De Ingenieria Genetica Y Biotecnologia Proteína nmb0928 y su uso en formulaciones farmaceuticas

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EPO Proteins [online] 31 May 2006 (2006-05-31), "Sequence 6822 from Patent WO2000071725.", XP002464619, retrieved from EBI accession no. EPOP:CS295382 Database accession no. CS295382 *
DATABASE Geneseq [online] 7 March 2003 (2003-03-07), "N. gonorrhoeae amino acid sequence SEQ ID 2320.", XP002464620, retrieved from EBI accession no. GSP:ABP77895 Database accession no. ABP77895 *
DATABASE UniProt [online] 1 October 2000 (2000-10-01), "Putative uncharacterized protein.", XP002464621, retrieved from EBI accession no. UNIPROT:Q9K0J1 Database accession no. Q9K0J1 *
GIULIANI MARZIA M ET AL: "A universal vaccine for serogroup B meningococcus", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 103, no. 29, 18 July 2006 (2006-07-18), pages 10834 - 10839, XP002450501, ISSN: 0027-8424 *
PIZZA M ET AL: "IDENTIFICATION OF VACCINE CANDIDATES AGAINST SEROGROUP B MENINGOCOCCUS BY WHOLE-GENOME SEQUENCING", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 287, 2000, pages 1816 - 1820, XP000914964, ISSN: 0036-8075 *
TANG C ET AL: "For discussion: live attenuated vaccines for group B meningococcus", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 2, January 1999 (1999-01-01), pages 114 - 117, XP004139965, ISSN: 0264-410X *
TETTELIN H ET AL: "Complete genome sequence of Neisseria meningitidis serogroup B strain MC58", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 287, no. 5459, 10 March 2000 (2000-03-10), pages 1809 - 1815, XP002230293, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
EP2011509A2 (en) 2009-01-07
BRPI0709922A2 (pt) 2011-07-26
AR060797A1 (es) 2008-07-16
ZA200808768B (en) 2009-07-29
CA2647465A1 (en) 2007-10-11
CU23575A1 (es) 2010-09-30
KR20080108576A (ko) 2008-12-15
CN101448518A (zh) 2009-06-03
NO20084525L (no) 2008-11-28
WO2007112703A2 (es) 2007-10-11
MX2008012665A (es) 2008-10-13
US20100129387A1 (en) 2010-05-27
AU2007234214A1 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
BRPI0716145A2 (pt) formuaÇço de vacina, mÉtodo de adaptaÇço e propagaÇço do vÍrus chikungunya, mÉtodo de concentraÇço e purificaÇço de vÍrus, composiÇço potencialmente imunogÊnica, sequÊncia de nucleotÍdeo, contruto de dna recombinante, mÉtodo para produzir proteÍna recombinante, composiÇço farmacÊutica, mÉtodo in vitro ou in vivo e mÉtodo para elicitar resposta imune protetora
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2007149715A3 (en) Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
WO2010066418A8 (de) Verwendung von flt3-ligand zur verstärkung von immunreaktionen bei rna-immunisierung
WO2007115578A8 (en) Synthetic mecp2 sequence for protein substitution therapy
NZ601538A (en) Vaccine compositions comprising a mutated factor h binding protein
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
WO2005084306A3 (en) Immunogenic compositions for chlamydia pneunomiae
WO2008052173A8 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2008017826A3 (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
WO2007112702A3 (es) Composición farmacéutica que comprende la proteína nmb0938
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
WO2009037183A3 (de) Nukleinsäurehaltige kosmetische und/oder pharmazeutische zubereitung zur induktion antimikrobieller peptide in epithelialen deckgeweben
WO2007112703A3 (es) Composición farmacéutica que comprende la proteína nmb0606
WO2008127450A8 (en) Linear expression cassette vaccines
WO2007073705A3 (es) Composiciones farmacéuticas que contienen la proteína nma0939
WO2009130256A3 (en) Tat protein for preventing or treating aids
WO2009014382A3 (en) Cxcl11 adjuvant compositions and uses thereof
WO2006122986A3 (en) Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections
TH94299B (th) สูตรผสมทางเภสัชกรรมซึ่งมีโปรตีน nma0939
TH94322B (th) องค์ประกอบเภสัชกรรม ซึ่งมีโปรตีน nmb0606
WO2005123121A3 (en) Use of dna molecule as vaccine adjuvant

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780018286.4

Country of ref document: CN

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2647465

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 571614

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/012665

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 8525/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020087026335

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007234214

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007721809

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007234214

Country of ref document: AU

Date of ref document: 20070329

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12295198

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0709922

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080930

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)